Navigation Links
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
Date:1/8/2009

REHOVOT, Israel and JERSEY CITY, New Jersey, January 8 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today it has signed an exclusive distribution agreement with Teva Pharmaceutical Industries Ltd. Under the terms of the agreement Teva will offer Rosetta Genomics' miRview(TM) tests in Israel and Turkey. The terms of the deal were not disclosed.

"This is yet another important step in Rosetta Genomics' commercialization efforts," noted Ronen Tamir, Chief Commercialization Officer at Rosetta Genomics. "As Israel provided its citizens with health insurance under the National Health Law, it represents a very attractive market for us. Teva has gained unsurpassed experience in marketing and obtaining reimbursement for complex molecular tests in Israel, and we are very excited to be partnering with them on these important tests. We are also excited to have Teva distribute our tests in Turkey, a country with significant market potential."

Using microRNAs, a group of recently discovered non-coding genes found to be highly sensitive biomarkers, Rosetta Genomics has developed proprietary technologies which can be the basis for a wide range of diagnostic tests.

The following tests will be distributed by Teva Pharmaceuticals:

- miRview(TM) mets - This test can accurately identify the primary tumor site in patients presenting with metastatic cancer, as well in patients whose tumor has not been identified, and consequently been labeled Cancer of Unknown Primary (CUP). As metastases need to be treated according to their primary origin, accurate identification of the metastases' primary origin can be critical for determining appropriate treatment.Current diagnostic methods to identify the origin of a metastasis include a wide range of costly, time consuming, and at times inefficient tests. miRview(TM) mets
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... Senior supply chain management executives from ... the challenges of “Reducing Cost, Lead Time, & Defects ... sourcing. Describing the partnership of the Bio Supply Management ... Institute ( SCMI) of the University of San ... the Kroc Institute of Peace and Justice in San ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... Helena Rojas to Director of Global Business Development Operations , ... ... Ltd., a leading provider of multilingual localization, testing and outsourced software ... to Vice President of Global Business Development and Helena Rojas to ...
... China, March 4 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited ... manufacturer and,marketer of medical devices worldwide, today announced ... Officer of the Company effective as of May ... step down from the role of Chief,Financial Officer ...
... 4 The Healthcare practice at Frost ... 2009 Quarterly Analyst Briefing Presentation on the North ... March 5, 2009 at 10:00 a.m. PST. (Logo: ... growth and is experiencing several notable trends, such ...
Cached Biology Technology:Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 2Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 3Mindray Appoints Mr. Ronald Ede as Chief Financial Officer 2Mindray Appoints Mr. Ronald Ede as Chief Financial Officer 3Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells 2
(Date:7/11/2014)... When researchers at the National Institute of Standards ... do their work more effectively, they often prove ... Such was the case recently for M. Lorna ... in the growing specialization of glycomics. Glycomics is ... called glycans that are attached to proteins and ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... evidence that under the normal circumstances, astrocytes ... maintain neuronal environment, and exhibit therapeutic and ... disease. Previous studies have found that nerve ... chemical induction have reduced viability, which produces ... Xiaodong Yuan, Kailuan General Hospital, Hebei United ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... with colleagues from the Botswana National Museum shed new ... to southern Africa and from where. A domestic cow ... from a site at Toteng, located in the Kalahari ... Accelerator Mass Spectrometry (AMS) radiocarbon technique, provides the oldest ...
... found that the two primary areas of the human ... cortex used in higher-level thought undergoes more extensive changes ... such as heartbeat, breathing and balance. Their work, based ... of human and chimpanzee brains, also shows that the ...
... first time used gene therapy to successfully treat heart ... model that is genetically susceptible to a human muscular ... journal Circulation, the authors say that this is the ... the body. , "Previous attempts at systemic gene therapy ...
Cached Biology News:Human cerebellum and cortex age in very different ways 2Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 2Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 3Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 4
... Flat bottoms,• Nonreversible ... to reduce contamination,• Individual ... identification,• Uniform footprint for ... for optimal cell attachment,• ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Biology Products: